Published in Transplantation on March 01, 1976
Serological aspects of rat tumour xenograft growth in athymic nude mice. Br J Cancer (1979) 0.76
Tumour markers with unknown functions in gynaecological neoplasia. Arch Gynecol (1980) 0.75
Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nat New Biol (1972) 4.04
A phase I/II study of trichosanthin treatment of HIV disease. AIDS (1990) 2.26
Demonstration of tumour-specific humoral antibody against aminoazo dye-induced rat hepatomata. Br J Cancer (1967) 2.23
The influence of tumour cell DNA abnormalities on survival in colorectal cancer. Br J Surg (1985) 2.20
Tumour-specific immunity against spontaneous rat tumours. Int J Cancer (1966) 1.83
Demonstration of cell-surface antigens on chemically induced tumors. Ann N Y Acad Sci (1971) 1.78
A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. Histopathology (1984) 1.72
Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet (1982) 1.71
Tumour-specific antigenicity of aminoazo-dye-induced rat hepatomas. Int J Cancer (1967) 1.62
Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line. Br J Cancer (1981) 1.61
Influence of BCG infection on growth of 3-methylcholanthrene-induced rat sarcomas. Rev Eur Etud Clin Biol (1971) 1.60
BCG immunotherapy of a rat sarcoma. Br J Cancer (1973) 1.50
Inhibition of hepatoma-immune lymph-node cell cytotoxicity by tumour-bearer serum, and solubilized hepatoma antigen. Int J Cancer (1973) 1.49
BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells. Br J Cancer (1973) 1.49
Cellular and humoral immunity to rat hepatoma-specific antigens correlated with tumour status. Int J Cancer (1973) 1.48
Solubilization of tumour-specific antigen from plasma membrane of an aminoazo-dye-induced rat hepatoma. Clin Exp Immunol (1972) 1.41
Studies on the immunobiology of rnu/rnu "nude" rats with congenital aplasia of the thymus. Eur J Immunol (1980) 1.36
Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro. Int J Cancer (1983) 1.35
Immunological aspects of chemical carcinogenesis. Adv Cancer Res (1973) 1.31
Neoantigens on spontaneous and carcinogen-induced rat tumors defined by in vitro lymphocytotoxicity assays. Int J Cancer (1974) 1.30
Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. Br Med J (Clin Res Ed) (1985) 1.29
BCG immunotherapy of rat tumours in athymic nude mice. Nature (1975) 1.27
Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol (1990) 1.27
Phenotype of rat natural killer cells defined by monoclonal antibodies marking rat lymphocyte subsets. Immunology (1982) 1.25
Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. Br J Cancer (1987) 1.23
Isolation of membrane-associated tumour-specific antigen from an aminoazo-dye-induced rat hepatoma. Int J Cancer (1969) 1.21
Immunogenic properties of rat hepatoma subcellular fractions. Br J Cancer (1974) 1.20
Detection and isolation of tumour-specific antigen associated with a spontaneously arising rat mammary carcinoma. Int J Cancer (1970) 1.20
Embryonic antigen expression on experimental rat tumours. Transplant Rev (1974) 1.20
Demonstration by colony inhibition methods of cellular and humoral immune reactions to tumour-specific antigens associated with aminoazo-dye-induced rat hepatomas. Int J Cancer (1971) 1.19
Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology (1989) 1.18
A monoclonal antibody against human colonic adenoma recognizes difucosylated Type-2-blood-group chains. Biosci Rep (1983) 1.18
Detection of circulating hepatoma D23 antigen and immune complexes in tumour bearer serum. Br J Cancer (1973) 1.17
Association between clinical symptoms and lymphocyte abnormalities in a population with chronic domestic exposure to industrial solvent-contaminated domestic water supply and a high incidence of leukaemia. Cancer Immunol Immunother (1988) 1.17
Embryonic antigen expression in chemically induced rat hepatomas and sarcomas. Int J Cancer (1972) 1.17
Inhibition of lymphocyte cytotoxicity for human colon carcinoma by treatment with solubilized tumour membrane fractions. Int J Cancer (1973) 1.16
Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res (1991) 1.14
Circulating immune complexes in patients with breast cancer. Br Med J (1977) 1.14
BGG immunotherapy of local subcutaneous growths and post-surgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin. Int J Cancer (1973) 1.13
Characteristics of a cell surface antigen defined by an anti-human osteogenic sarcoma monoclonal antibody. Eur J Cancer Clin Oncol (1983) 1.12
Modification of the immunogenicity and antigenicity of rat hepatoma cells. I. Cell-surface stabilization with glutaraldehyde. Br J Cancer (1979) 1.09
Kinetics of divalent monoclonal antibody binding to tumour cell surface antigens using flow cytometry: standardization and mathematical analysis. Mol Immunol (1985) 1.09
Fractionation of plasma membrane-associated tumor-specific antigen from an aminoazo dye-induced rat hepatoma. Int J Cancer (1973) 1.08
The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients. J Nucl Med (1985) 1.07
Association of antigen expression and DNA ploidy in human colorectal tumors. Cancer Res (1986) 1.06
BCG in tumor immunotherapy. Adv Cancer Res (1978) 1.06
Cell-mediated and humoral immune reactions to human tumours. Int J Cancer (1973) 1.05
C595--a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer (1990) 1.05
Rat lymphocyte subsets: cellular requirements for the generation of T-cell growth factor. Cell Immunol (1982) 1.05
Immunology of spontaneously arising rat mammary adenocarcinomas. Int J Cancer (1969) 1.05
Immunohistochemical localization of Y hapten and the structurally related H type-2 blood-group antigen on large-bowel tumours and normal adult tissues. Int J Cancer (1984) 1.04
Humoral factors abrogating cell-mediated immunity in the tumor-bearing host. Curr Top Microbiol Immunol (1975) 1.04
Tumor antigens and tumor-host relationships. Annu Rev Med (1976) 1.03
131I and 111In-labelled monoclonal antibody imaging of primary lung carcinoma. Nucl Med Commun (1986) 1.03
Tumour aneuploidy, prognostic parameters and survival in primary breast cancer. Br J Cancer (1987) 1.03
Distribution of a basic azo-dye-binding protein in normal rat tissues anc carcinogen-induced hepatomata. Br J Cancer (1968) 1.03
Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate. Br J Cancer (1983) 1.02
Influence of whole body irradiation on bcg contact suppression of a rat sarcoma and tumour-specific immunity. Br J Cancer (1976) 1.02
BCG immunotherapy of rat tumors of defined immunogenicity. Natl Cancer Inst Monogr (1973) 1.02
Induction of delayed hypersensitivity to human tumor cells with a human monoclonal anti-idiotypic antibody. J Natl Cancer Inst (1991) 1.01
Radiation-killed BCG in the treatment of transplanted rat tumours. Int J Cancer (1974) 1.01
Antigenicity of newly established colorectal carcinoma cell lines. Br J Cancer (1986) 1.00
Localisation of human osteosarcoma by antitumour monoclonal antibody. J Bone Joint Surg Br (1983) 1.00
Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression. Br J Cancer (1987) 1.00
Tumour specific antigens associated with chemically induced tumours. Rev Eur Etud Clin Biol (1970) 0.97
Circulating immune complexes in rats bearing chemically induced tumours. II. Characterization of sera from different stages of tumour growth. Int J Cancer (1978) 0.97
The localization of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumours. Br J Surg (1984) 0.97
Tumour-specific complement-dependent serum cytotoxicity against a chemically induced rat hepatoma. Int J Cancer (1977) 0.97
Monoclonal antibody against a naturally occurring rat mammary carcinoma. Int J Cancer (1980) 0.97
Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumour activity. Int J Cancer (1984) 0.97
An immunofluorescent test for faecal occult blood. Lancet (1981) 0.96
Antigen deletions in carcinogen-induced rat hepatomata. Nature (1967) 0.96
Antigenic differences between primary methylcholanthrene-induced rat sarcomas and post-surgical recurrences. Int J Cancer (1977) 0.95
Immunogenicity of rat hepatoma membrane fractions. Br J Cancer (1973) 0.95
Subpopulations of multiparous rat lymph-node cells cytotoxic for rat tumour cells and capable of suppressing cytotoxicity in vitro. Int J Cancer (1975) 0.95
Modification of the immunogenicity and antigenicity of rat hepatoma cells. II. Mild heat treatment. Br J Cancer (1979) 0.95
Detection of either rapidly cytolytic macrophages or NK cells in "activated" peritoneal exudates depends on the method of analysis and the target cell type. Immunology (1981) 0.94
The expression of a phase-specific foetal antigen on rat embryo cells. Transplantation (1974) 0.94
Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA. Cancer Immunol Immunother (1987) 0.94
In vitro assays of cell-mediated immunity to human solid tumors: problems of quantitation, specificity, and interpretation. J Natl Cancer Inst (1975) 0.93
Preparation of aminoazo dye induced rat hepatoma membrane fractions retaining tumour specific antigen. Br J Cancer (1974) 0.93
Immunotherapy of an ascitic rat hepatoma with cord factor (trehalose-6, 6'-dimycolate) and synthetic analogues. Int J Cancer (1979) 0.93
Multiple epitopes on a human breast-carcinoma-associated antigen. Int J Cancer (1985) 0.93
A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents. AIDS Res Hum Retroviruses (1994) 0.93
Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting. Cancer Metastasis Rev (1983) 0.92
Imaging of primary and metastatic colorectal cancer using an 111In-labelled antitumour monoclonal antibody (791T/36). Nucl Med Commun (1985) 0.92
Immunogenicity of embryonic antigens associated with chemically induced rat tumours. Int J Cancer (1974) 0.91
Epitopes with diagnostic and prognostic significance co-expressed on a human breast carcinoma-associated antigen. Eur J Cancer Clin Oncol (1986) 0.91
Multiple antigenic specificities within primary 3-methylcholanthrene-induced rat sarcomas and metastases. Int J Cancer (1980) 0.91
Significance of serum factors modifying cellular immune responses to growing tumours. Br J Cancer Suppl (1973) 0.91
Serum factors modifying cell mediated immunity to rat hepatoma d23 correlated with tumour growth. Int J Cancer (1975) 0.90
Differentiation between the embryonic and tumour specific antigens on chemically induced rat tumours. Br J Cancer (1974) 0.90
Assessment of cell-mediated immunity to human tumor-associated antigens. Int Rev Exp Pathol (1977) 0.90
Assessment of cell-mediated immunity to malignant mesothelioma by microcytotoxicity tests. Int J Cancer (1976) 0.90
BCG therapy of pleural and peritoneal growth of transplanted rat tumours. Int J Cancer (1975) 0.90
Quantitative studies of natural immunity to solid tumours in rats. The nature of the killer cell depends on the type of assay. Immunology (1980) 0.90
Flow cytometric analysis of the DNA content of gastric cancer. Br J Cancer (1987) 0.89
Inhibition of cell-mediated cytotoxicity to chemically induced rat tumours by soluble tumour and embryo cell extracts. Int J Cancer (1976) 0.89